Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS Income Before Tax

Profit after all operating and non-operating items but before income tax.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -$110.11M, compared with -$128.39M a year earlier. Trailing-twelve-month income before tax was -$543.8M.

Context

  • Income before tax amounted to 40.3% of revenue in FY2025, down 25.0 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$110.11M or moves back toward the trailing-twelve-month quarterly average of -$135.95M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$110.11M+2.9% QoQ
Last fiscal yearDec 2025
-$380M+17.4% YoY
LTMSep 2026
-$543.8M-110.2% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.2%——
1 year+17.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(380M) USD
Year-over-year change
+17.4%

Income Before Tax vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's LTM Sep 2026 income before tax of -$543.8M is the 6th highest of the 9 companies compared; the peer median is -$230.84M.
  • Its year-over-year change of -110.2% is the 8th highest of 9, against a peer median of -0.5%.
  • Income before tax amounts to 56.7% of revenue for IONS, versus a peer median of 14.7%.
IONS Competitors Peer median
Income Before Tax for IONS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$856.4M -52.4%-26.9%8.6%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$799.57M +310.6%—16.6%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$24.47M +114.9%—1.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$67.07M -110.1%—6.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$394.6M +25.0%—597.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$543.8M -110.2%—56.7%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$605.54M -10.7%—90.5%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$706.17M +9.7%—99.0%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$131.59B -19472.7%+47.8%12.8%
Peer median (excluding IONS) -$230.84M-0.5%+10.4%14.7%

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue810.46M587.37M787.65M705.14M944M
Cost of Revenue10.84M14.12M9.13M11.22M16M
Gross Profit799.61M573.25M778.51M693.92M928M
Gross Margin98.7%97.6%98.8%98.4%98.3%
Research & Development643M833M899.63M901.53M916M
Selling, General & Admin170.9M150.3M232.6M267.5M394M
Operating Expenses829.8M983.44M1.13B1.17B1.31B
Depreciation & Amortization19.56M22.11M22.5M21.99M22.69M
EBITDA(5.19M)(227.76M)(235.87M)(353.72M)(284.31M)
EBITDA Margin-0.6%-38.8%-29.9%-50.2%-30.1%
Operating Income(30.19M)(410.19M)(353.73M)(475.08M)(382M)
Operating Margin-3.7%-69.8%-44.9%-67.4%-40.5%
Interest Income10.04M25.33M89.04M107.02M97.77M
Interest Expense9.35M8.12M81.46M90.45M90.54M
Other Income / Expenses1.04M152.21M19.77M15.01M2M
Income Before Tax(29.15M)(257.99M)(333.97M)(460.07M)(380M)
Pre-Tax Margin-3.6%-43.9%-42.4%-65.2%-40.3%
Income Tax Expense(551K)11.74M32.32M(6.17M)1M
Net Income(28.6M)(269.72M)(366.29M)(453.9M)(381M)
Net Margin-3.5%-45.9%-46.5%-64.4%-40.4%
EPS (Basic)(0.20)(1.90)(2.56)(3.04)(2.38)
EPS (Diluted)(0.20)(1.90)(2.56)(3.04)(2.38)
Weighted Avg Shares141.02M141.85M143M149.51M160M
Weighted Avg Shares (Diluted)141.02M141.85M143.19M149.51M160M

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.